Sensei Biotherapeutics (NASDAQ:SNSE) Announces Quarterly Earnings Results

Sensei Biotherapeutics (NASDAQ:SNSE) released its earnings results on Friday. The company reported ($131.45) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($130.83), FiscalAI reports.

Sensei Biotherapeutics Stock Up 3.1%

NASDAQ SNSE traded up $0.61 on Friday, hitting $20.43. 40,624 shares of the stock were exchanged, compared to its average volume of 223,122. Sensei Biotherapeutics has a fifty-two week low of $5.25 and a fifty-two week high of $36.76. The company has a market cap of $27.40 million, a PE ratio of -1.23 and a beta of -0.18. The company has a 50-day moving average price of $29.11 and a 200-day moving average price of $17.85.

Key Sensei Biotherapeutics News

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Insider Buying and Selling

In other news, major shareholder Millennium Management Llc purchased 15,321 shares of the stock in a transaction on Friday, March 27th. The stock was bought at an average price of $26.61 per share, for a total transaction of $407,691.81. Following the acquisition, the insider directly owned 142,360 shares of the company’s stock, valued at approximately $3,788,199.60. The trade was a 12.06% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders have purchased 46,980 shares of company stock worth $1,341,669 and have sold 23,067 shares worth $704,439. 23.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC boosted its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned about 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. 10.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on SNSE. Leerink Partners started coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They issued an “outperform” rating and a $50.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Friday, April 24th. Finally, Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $40.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.